| CONTACT |
Andrew Ayscough, previously director of research at British Biotech Pharmaceuticals, has been appointed director of chemistry at Inpharmatica. While at British Biotech, he directed projects in cancer and anti-infectives and managed collaborations with the company's partners. He received a B.S. in chemistry from the University of Bath, in England, and a doctorate from the University of Oxford. Edwin Moses, nonexecutive director of Inpharmatica since July 2001, has been appointed nonexecutive chairman. He was previously CEO and then executive chairman of Oxford Asymmetry International, overseeing its merger with Evotec BioSystems in 2000. Moses received a doctorate in chemistry from Sheffield University, in England, and was awarded a Royal Society/NATO postdoctoral fellowship for studies in biophysical chemistry at Regensburg University, in Germany. |
|
Want more information ? Interested in the hidden information ? Click here and do your request. |